This study quantified patient preferences for generalized myasthenia gravis (gMG) treatment features.

gMG is a chronic condition characterized by severe muscle weakness. Emerging gMG treatments have limited clinical differentiation but vary considerably in their administration.

The 200 respondents (US, n=150; UK, n=25; Germany, n=25) placed the most importance on changes in risk of ISR (from 40% to 0% [mild-to-moderate], CRAI=23.4%; from 10% to 0% [severe], CRAI=22.2%) and frequency of administration (from once daily to once every 8 weeks, CRAI=20.4%). While changes in setting and administration mode were the least important (CRAI = 10.3% and 10.0%, respectively), self-administration at home was preferred to administration by a doctor or nurse in a healthcare facility. Model estimates suggest respondents were more likely to choose a treatment self-administered at home once-a-day through a prefilled syringe with 2 weeks until onset of action (65.2%) over a treatment administered once every 8 weeks through a 1- to 2-hour IV at a medical facility with 4 weeks until onset of action (34.8%).

Respondents preferred gMG treatments with lower ISR risk, less frequent administration, and those self-administered at home. However, respondents were willing to trade off among treatment attributes, suggesting an important role for patient preferences in treatment selection.